Full Breakdown
FDA Advisory Panel Endorses Grail’s Galleri Multi-Cancer Blood Test
By Drooid · · How we work
Core Event
On September 23, a panel of external experts advising the U.S. Food and Drug Administration (FDA) voted that the benefits of Grail Inc.’s Galleri blood test outweigh its risks for adults 50 years and older. The panel’s votes were 7-2 with one abstention on the benefit-risk question, 10-0 on safety, and 6-4 on efficacy. The advisory group’s recommendation is non-binding, and the FDA will issue a final decision in the coming months.
Background & Context
Galleri is a blood-based multi-cancer early detection (MCED) test that analyzes cancer-specific methylation patterns in cell-free DNA. Grail submitted a Premarket Approval (PMA) application on January 29, 2026. The FDA’s review relies on two pivotal studies: the U.K. NHS-Galleri trial (?142,000 participants) and the U.S. PATHFINDER 2 study (?35,000 participants). Both evaluated an earlier investigational version of the assay and then applied the current Galleri test to stored samples.
Data & Statistics
- Safety: Unanimous 10-0 vote that the test is safe.
- Efficacy: 6-4 vote indicating “reasonable assurance” of effectiveness.
- Specificity: 99.85 % (PATHFINDER 2) and 99.74 % (NHS-Galleri).
- Sensitivity (12-month episode): 35.0 % (PATHFINDER 2) and 31.6 % (NHS-Galleri).
- Positive predictive value: 77 % (PATHFINDER 2) and 66.2 % (NHS-Galleri).
- Cancer detection rate: About 0.5 % (?200 screens per cancer detected).
- Stage-specific detection: In NHS-Galleri, 20.5 % of stage I-II cancers were identified; sensitivity rose to 60 % for stage IV disease.
- U.K. trial outcome: No statistically significant reduction in late-stage (stage 3-4) diagnoses.
Official Statements & Responses
The panel’s written recommendation emphasized that Galleri should supplement, not replace, guideline-recommended screenings such as mammograms and colonoscopies. FDA staff noted no major concerns about analytical performance or primary safety analyses but highlighted unanswered questions about the “early detection” label and the test’s ability to improve outcomes for cancers that already have established screening programs. Grail’s submission includes one-year follow-up data from 25,490 PATHFINDER 2 participants and data from more than 70,000 NHS-Galleri participants.
Verbatim Quotes
- “This increases our confidence even more on FDA approval — almost derisked,” — Subbu Nambi, analyst at Guggenheim
- “That’s why nobody in the oncology community is recommending this test,” — Dr. Scott Ramsey
- “Patients want opportunity, they want options,” — Dr. Mylynda Massart, University of Pittsburgh
What’s Next
The FDA is expected to issue its final decision on Galleri in early 2027. If approved, the test could become eligible for coverage under Medicare and private insurers, expanding access beyond the current out-of-pocket model that costs roughly $700–$950 per test.